Gland Pharma Limited has officially announced the reappointment of Ms. Naina Lal Kidwai as an Independent Director. Her second consecutive term of five years is effective from May 17, 2026, and will run through May 16, 2031. The company will seek formal shareholder approval for this appointment through an upcoming postal ballot and e-voting process.
Board Appointment Details
Following a recent meeting held on April 9, 2026, the Board of Directors of Gland Pharma Limited has approved the continuation of Ms. Naina Lal Kidwai on the company’s board. Ms. Kidwai, who initially began her term in May 2021, will now serve her second five-year term as an Independent Director.
Profile and Expertise
Ms. Naina Lal Kidwai brings an extensive background in finance, private equity, and corporate leadership. She currently serves as the Chairman of Rothschild & Co India and holds senior advisory roles with Advent Private Equity, TPG Rise Climate, and Lightspeed Venture Partners. Additionally, she holds non-executive board positions at several prominent organizations, including Holcim, UPL, and Biocon.
Her distinguished career includes a tenure as the Past President of FICCI and as a former executive leader at HSBC Asia Pacific. A graduate of the Harvard Business School, Ms. Kidwai has been recognized with the Padma Shri for her significant contributions to trade and industry. Beyond her corporate achievements, she is deeply involved in policy and advocacy, having chaired various committees related to environment, sanitation, and finance, and is a prolific author on leadership and sustainability.
Source: BSE
